127 related articles for article (PubMed ID: 24503787)
21. Hypo- or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer.
Zhang J; Fan M; Liu D; Zhao KL; Wu KL; Zhao WX; Zhu ZF; Fu XL
Radiat Oncol; 2017 Mar; 12(1):51. PubMed ID: 28283034
[TBL] [Abstract][Full Text] [Related]
22. Limited-stage small-cell lung cancer treated with early chemo-radiotherapy: the impact of effective chemotherapy.
Scotti V; Meattini I; Saieva C; Rampini A; De Luca Cardillo C; Bastiani P; Mangoni M; Agresti B; Santomaggio C; Di Cataldo V; Franzese C; Livi L; Magrini SM; Biti G
Tumori; 2012; 98(1):53-9. PubMed ID: 22495702
[TBL] [Abstract][Full Text] [Related]
23. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
[TBL] [Abstract][Full Text] [Related]
24. Comparison of treatment outcomes between involved-field and elective nodal irradiation in limited-stage small cell lung cancer.
Han TJ; Kim HJ; Wu HG; Heo DS; Kim YW; Lee SH
Jpn J Clin Oncol; 2012 Oct; 42(10):948-54. PubMed ID: 22811409
[TBL] [Abstract][Full Text] [Related]
25. Impact of prophylactic cranial irradiation timing on brain relapse rates in patients with stage IIIB non-small-cell lung carcinoma treated with two different chemoradiotherapy regimens.
Topkan E; Parlak C; Kotek A; Yuksel O; Cengiz M; Ozsahin M; Pehlivan B
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1264-71. PubMed ID: 22172902
[TBL] [Abstract][Full Text] [Related]
26. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
Johnson BE; Bridges JD; Sobczeck M; Gray J; Linnoila RI; Gazdar AF; Hankins L; Steinberg SM; Edison M; Frame JN; Pass H; Nesbitt J; Holden D; Mulshine JL; Glatstein E; Ihde DC
J Clin Oncol; 1996 Mar; 14(3):806-13. PubMed ID: 8622028
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.
Okuma HS; Horinouchi H; Kitahara S; Asao T; Sunami K; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Ohe Y
Clin Lung Cancer; 2017 Mar; 18(2):234-240.e2. PubMed ID: 27867001
[TBL] [Abstract][Full Text] [Related]
28. Intensive combination chemotherapy, concurrent chest irradiation, and warfarin for the treatment of limited-disease small-cell lung cancer: a Cancer and Leukemia Group B pilot study.
Aisner J; Goutsou M; Maurer LH; Cooper R; Chahinian P; Carey R; Skarin A; Slawson R; Perry MC; Green MR
J Clin Oncol; 1992 Aug; 10(8):1230-6. PubMed ID: 1321892
[TBL] [Abstract][Full Text] [Related]
29. Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience.
Mertsoylu H; Köse F; Sümbül AT; Sedef AM; Doğan Ö; Besen AA; Parlak C; Fındıkçıoğlu A; Muallaoğlu S; Sezer A; Sakallı H; Özyılkan Ö
Med Sci Monit; 2015 Mar; 21():661-6. PubMed ID: 25731741
[TBL] [Abstract][Full Text] [Related]
30. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.
Curran WJ; Paulus R; Langer CJ; Komaki R; Lee JS; Hauser S; Movsas B; Wasserman T; Rosenthal SA; Gore E; Machtay M; Sause W; Cox JD
J Natl Cancer Inst; 2011 Oct; 103(19):1452-60. PubMed ID: 21903745
[TBL] [Abstract][Full Text] [Related]
31. Long-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain radiotherapy and thoracic chemoradiation.
Arrieta O; Villarreal-Garza C; Zamora J; Blake-Cerda M; de la Mata MD; Zavala DG; Muñiz-Hernández S; de la Garza J
Radiat Oncol; 2011 Nov; 6():166. PubMed ID: 22118497
[TBL] [Abstract][Full Text] [Related]
32. Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?
Hendriks LEL; Brouns -JWM; Amini M; Uyterlinde W; Wijsman R; Bussink J; Biesma B; Oei SB; Stigt JA; Bootsma GP; Belderbos JSA; De Ruysscher DKM; Van den Heuvel MM; Dingemans AC
Lung Cancer; 2016 Nov; 101():68-75. PubMed ID: 27794410
[TBL] [Abstract][Full Text] [Related]
33. Trimodality therapy for superior sulcus tumours: evolution and evaluation of a treatment protocol.
Vos CG; Hartemink KJ; Blaauwgeers JL; Oosterhuis JW; Senan S; Smit EF; Thunnissen E; Paul MA
Eur J Surg Oncol; 2013 Feb; 39(2):197-203. PubMed ID: 23062624
[TBL] [Abstract][Full Text] [Related]
34. A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235).
McClay EF; Bogart J; Herndon JE; Watson D; Evans L; Seagren SL; Green MR;
Am J Clin Oncol; 2005 Feb; 28(1):81-90. PubMed ID: 15685040
[TBL] [Abstract][Full Text] [Related]
35. Simultaneous chemoradiotherapy with irinotecan and cisplatin in limited disease small cell lung cancer: a phase I study.
Klautke G; Fähndrich S; Semrau S; Büscher C; Virchow C; Fietkau R
Lung Cancer; 2006 Aug; 53(2):183-8. PubMed ID: 16757061
[TBL] [Abstract][Full Text] [Related]
36. HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer.
Zhai Y; Ma H; Hui Z; Zhao L; Li D; Liang J; Wang X; Xu L; Chen B; Tang Y; Wu R; Xu Y; Pang Q; Chen M; Wang L
Radiother Oncol; 2019 Feb; 131():27-34. PubMed ID: 30773184
[TBL] [Abstract][Full Text] [Related]
37. Limited stage small cell lung cancer: treatment and therapy.
Turrisi AT
Curr Treat Options Oncol; 2003 Feb; 4(1):61-4. PubMed ID: 12525280
[TBL] [Abstract][Full Text] [Related]
38. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG).
Skarlos DV; Samantas E; Briassoulis E; Panoussaki E; Pavlidis N; Kalofonos HP; Kardamakis D; Tsiakopoulos E; Kosmidis P; Tsavdaridis D; Tzitzikas J; Tsekeris P; Kouvatseas G; Zamboglou N; Fountzilas G
Ann Oncol; 2001 Sep; 12(9):1231-8. PubMed ID: 11697833
[TBL] [Abstract][Full Text] [Related]
39. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
Bunn PA; Crowley J; Kelly K; Hazuka MB; Beasley K; Upchurch C; Livingston R; Weiss GR; Hicks WJ; Gandara DR
J Clin Oncol; 1995 Jul; 13(7):1632-41. PubMed ID: 7602352
[TBL] [Abstract][Full Text] [Related]
40. Duration of Twice-Daily Thoracic Radiotherapy and Time From the Start of Any Treatment to the End of Chest Irradiation as Significant Predictors of Outcomes in Limited-Disease Small-Cell Lung Cancer.
Morimoto M; Okishio K; Akira M; Omachi N; Tamiya A; Asami K; Kawaguchi T; Atagi S
Clin Lung Cancer; 2017 Mar; 18(2):e117-e127. PubMed ID: 28340925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
